Listen & Watch

  1. Cell & Gene Live Audience Q&A 9/16/2022

    During the hour, audience members submitted their questions for our panelists. To no surprise, they asked thoughtful, solid questions on everything from transecting cells with multiple RNA and the challenges associated with chronic dosing of mRNA therapeutics to the regulatory challenges around mRNA cell therapies.

  2. The Not-So-New Challenges Of mRNA Delivery 9/16/2022

    Walter Strapps, Ph.D., CEO of Carver Biosciences states that when it comes to mRNA, the challenges associated with its delivery are anything but new. Indeed, Strapps explains that challenges have existed essentially since the dawn of nucleotide therapeutics in general. “There is a joke within the oligo nucleotide field similar to the real estate industry in that in real estate it’s location, location, location; for all nucleotides it's delivery, delivery, delivery,” says Strapps.

  3. Advancements In Targeted mRNA Delivery 5/26/2022

    mRNA has broad potential as a therapeutic. The clinical translation of mRNA therapeutics has been made possible through advances in the design of mRNA manufacturing and intracellular delivery methods. However, broad application of mRNA is still limited by the need for improved delivery systems.

  4. CMC, Scale Up, & The Road To mRNA Regulatory Approval 3/16/2022

    Check out part two of our Bioprocess Online Live series on mRNA manufacturing challenges and opportunities. The panel discussion features Dr. Akhilesh Bhambhani, Sr. Director, Biologics Drug Product Development at Ultragenyx Pharmaceuticals and Roberta Duncan, VP and mRNA Program Lead at Seqirus. These two experts discuss some of the most critical steps to mRNA vaccine and therapeutic commercialization, including CMC, scale-up, tech transfer, and regulatory strategy.